TY - JOUR T1 - Increasing Trust in Real-World Evidence Through Evaluation of Observational Data Quality JF - medRxiv DO - 10.1101/2021.03.25.21254341 SP - 2021.03.25.21254341 AU - Clair Blacketer AU - Frank J Defalco AU - Patrick B Ryan AU - Peter R Rijnbeek Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254341.abstract N2 - Advances in standardization of observational healthcare data have enabled methodological breakthroughs, rapid global collaboration, and generation of real-world evidence to improve patient outcomes. Standardizations in data structure, such as use of Common Data Models (CDM), need to be coupled with standardized approaches for data quality assessment. To ensure confidence in real-world evidence generated from the analysis of real-world data, one must first have confidence in the data itself. The Data Quality Dashboard is an open-source R package that reports potential quality issues in an OMOP CDM instance through the systematic execution and summarization of over 3,300 configurable data quality checks. We describe the implementation of check types across a data quality framework of conformance, completeness, plausibility, with both verification and validation. We illustrate how data quality checks, paired with decision thresholds, can be configured to customize data quality reporting across a range of observational health data sources. We discuss how data quality reporting can become part of the overall real-world evidence generation and dissemination process to promote transparency and build confidence in the resulting output. Transparently communicating how well CDM standardized databases adhere to a set of quality measures adds a crucial piece that is currently missing from observational research. Assessing and improving the quality of our data will inherently improve the quality of the evidence we generate.Competing Interest StatementCB, FJD, and PBR are Janssen employees and own stock or stock options. PRR receives an unconditional grant from Janssen Research & Development, and funding through the Innovative Medicines Initiative.Funding StatementThis study was sponsored by Janssen Research & Development, LLC. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of IBM MarketScan® Multi-State Medicaid Database was reviewed by the New England Institutional Review Board and determined to be exempt from broad Institutional Review Board approval, as this research project did not involve human patient research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Data Quality Dashboard R package is available on github as is a publicly available instance of the data quality results for IBM MarketScan® Multi-State Medicaid. https://github.com/OHDSI/DataQualityDashboard/ https://data.ohdsi.org/DataQualityDashboardMDCD/ ER -